Faculty of AgriSciences - list of publicationsHelp


The following list contains all information available to the publication.

BODOOR, K. -- ALMOMANI, R. -- ALQUDAH, M. -- HADDAD, Y A E. -- SAMOURI, W. LAT1 (SLC7A5) overexpression in negative her2 group of breast cancer: A potential therapy target. Asian Pacific Journal of Cancer Prevention. 2020. v. 21, no. 5, p. 1453--1458. ISSN 1513-7368. URL: http://journal.waocp.org/article_89076.html

Original name:
LAT1 (SLC7A5) overexpression in negative her2 group of breast cancer: A potential therapy target
Czech name:
Written by (author): Khaldon Bodoor
Rowida Almomani
Mohammad Alqudah
Yazan Abdulmajeed Eyadh Haddad, Ph.D.
Walaa Samouri
Department:
Department of Chemistry and Biochemistry
Kind of publication:
article in a professional periodical
Periodical:
Asian Pacific Journal of Cancer Prevention
Nature of article: paper
Volume no. (year):
21
Periodical number within the volume:
5
Year of publication:
2020
Starting page:
1453
Up to page:
1458
Number of pages:
6
Sub-specification:
článek je obsažen v databázi SCOPUS
UT code by Web of Science:
EID code by Scopus:
Form of publication:
printed version
Original language:
English
Description in original language:
Objective: HER2 negative carcinomas of the breast pose a challenge for treatment due to redundancies in potential drug targets and poor patient outcomes. Our aim was to investigate the role of L-type amino acid transporter-LAT1 as a potential prognosticator and a drug target. Methods: In this retrospective work, we have studied the expression of LAT1 in 145 breast cancer tissues via immunohistochemistry. Overall survival analysis was used to evaluate patient outcome in various groups of our cohort. Results: Positive LAT1 expression was found in 27 (84.4%) luminal A subtype, 27 (64.3%) luminal B/triple positive subtype, 29 (82.9%) triple negative subtype, and 24 (66.7%) HER2-only positive subtype (p=0.1). Interestingly, negative correlation was found between LAT1 and HER2; where positive expression of LAT1 was found in 56 (83.6%) cases in negative HER2 group and 51 (65.4%) cases from positive HER2 group (p=0.01). Unfortunately, we were unable to report significant survival differences when LAT1 expression was studied in the negative HER2 group. Nevertheless, five incidents of mortality (out of 55) were reported in LAT1+/HER2-group compared to none in the LAT1-/HER2-group (N=11). Conclusion: Our findings of overexpression of LAT1 in negative HER2 group suggest a role of this protein as prognosticator and drug target in a challenging therapeutic cohort.
Description in English:
Description in Czech:
Year of submission:
2020
Year of transmission:
RIV identification number:
URL: http://journal.waocp.org/article_89076.html
 
Entry made by: Markéta Hejčová, DiS.
Last change:
06/12/2020 15:51 (Markéta Hejčová, DiS.)

Evaluation of publication:

1
2
3
4
5
        
1
2
3
4
5
bad
 
good
        
uninteresting
 
interesting
Assessed: 0
Average score: -
        Assessed: 0Average score: -
1
2
345
        
1
2
345
amateur
 
professional
        theoretical
 
practical
Assessed: 0Average score: -        Assessed: 0Average score: -


Source specification:

Asian Pacific Journal of Cancer Prevention. Goyang: ISSN 1513-7368.

Original name:
Asian Pacific Journal of Cancer Prevention
Czech name:
Written by (author):
Kind of publication: magazine
ISSN:
1513-7368
Country of publisher:
Republic of Korea
Place of publishing:
Goyang
Publisher:
Asian Pacific Organization for Cancer Prevention
URL:
Reviewed magazine: no
Original language:
English
Description in original language:
Description in English:
Description in Czech:
 
Entry made by:
Last change:
04/18/2017 08:53 (Šárka Novotná)

Evaluation of publication:

1
2
34
5
        
12345
bad
 
good
        
uninteresting
 
interesting
Assessed: 0Average score: -
        
Assessed: 0
Average score: -
1
2
3
4
5
        
1
2
3
4
5
amateur
 
professional        theoretical
 
practical
Assessed: 0Average score: -        
Assessed: 0
Average score: -